BGM Group is a China-based pharmaceutical and chemical manufacturer operating through a VIE structure. Its core business runs through Gansu QLS, a Chinese operating entity that BGM controls via contractual arrangements rather than direct equity ownership — meaning BGM shareholders hold stakes in a Cayman Islands holding company, not the underlying Chinese business. BGM's primary products are pharmaceutical and biological: licorice-based medications (including Gan Di Xin, a patented antitussive tablet), oxytetracycline antibiotics and APIs for both human and veterinary use, heparin sodium derived from pig intestines, and Ahan Antibacterial Paste, a TCM-based topical treatment. BGM also sells non-pharmaceutical products including natural sausage casings and organic fertilizers under the Xiongguan brand, primarily in western China. BGM sells to pharmaceutical distributors, corporate customers, and directly to other pharma companies that use its APIs, across more than 20 Chinese provinces. Revenue is driven by volume and market pricing, with unit economics in oxytetracycline tied to fermentation efficiency. Manufacturing runs across two sites in Gansu and Sichuan provinces. In late 2024, BGM issued shares to acquire Patriton, a subsidiary of insurance technology company CISG Holdings, and is now pursuing a parallel strategy in AI-driven insurance services — targeting sales, underwriting, and claims workflows — alongside applying AI tools to its biopharma operations.